Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Analysts Unconvinced By Sanofi Best-In-Class Claims For Sarclisa

Much Ground To Make Up On J&J's Darzalex

Executive Summary

Sanofi presented new data at a post-ASCO briefing to back its claim that Sarclisa can become the anti-CD38 of choice for the treatment of multiple myeloma ahead of Darzalex. The investment community is not so sure.

You may also be interested in...



Sanofi Challenges J&J’s Darzalex With Blackstone Pact For SC Sarclisa

The French major has entered a risk-sharing collaboration with Blackstone focused on a new formulation of multiple myeloma drug Sarclisa, which could help it take on market leader Darzalex.

$1bn Amunix Buy Brings Sanofi Next-Generation TCE Platform

The deal bolsters Sanofi’s immuno-oncology pipeline and marks its sixth acquisition this year.

GSK To Address Multiple Myeloma With First-In-Class Blenrep In EU

The European Commission’s approval of GlaxoSmithKline’s Blenrep is one of the first major fruits of a refocused pipeline and development strategy at the big pharma company.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel